Sanfang Tu

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

American journal of hematology

Blood cancer journal

Cancer science

Bone marrow transplantation

Zhujiang Hospital, Southern Medical University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zhujiang Hospital, Southern Medical University Nov 17 2018 - Dec 01 2019

China

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma :: hematology

Publications

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Yanjie He, Yuxing Hu, Honghao Zhang, Xiaoling Xie, Yu-Hua Li
Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. American journal of hematology 99 (7) (2024)
Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Yanjie He, Yuxing Hu, Honghao Zhang, Xiaoling Xie, Yu-Hua Li
Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. American journal of hematology 99 (7) (2024)
Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Yanjie He, Yuxing Hu, Honghao Zhang, Xiaoling Xie, Yu-Hua Li
Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. American journal of hematology (2024)
Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Yanjie He, Yuxing Hu, Honghao Zhang, Xiaoling Xie, Yu-Hua Li
Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. American journal of hematology 99 (7) (2024)
Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Yiqing Li, Zhenqian Huang, Qixin Sun, Changfen Huang, Xiaqi Nie, Zurong Yao, Pengcheng Shi, Yu Zhang, Xuejie Jiang, Qi-Fa Liu, Guo-Pan Yu
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study. Blood cancer journal 13 (1) (2023)
Shi Han, Lijuan Zhou, Youyou Chen, Xuan Zhou, Zhenling Guo, Jilong Yang, Bo Jin, Yuchen Liu, Lung-Ji Chang, Yuhua Li, Sanfang Tu
The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study. Bone marrow transplantation 57 (3) (2022)
Zhenling Guo, Sanfang Tu, Siyao Yu, Liufang Wu, Wanying Pan, Ning Chang, Xuan Zhou, Chaoyang Song, Yuhua Li, Yanjie He
Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer science 112 (4) (2021)
Sanfang Tu, Rui Huang, Zhenling Guo, Lan Deng, Chaoyang Song, Xuan Zhou, Chunyan Yue, Lenghe Zhang, Yanjie He, Jilong Yang, Zhao Liang, Jingwen Du, Peihua Cao, Yushen Li, Lung-Ji Chang, Yuhua Li
Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome. American journal of hematology 94 (12) (2019)

Sanfang Tu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sanfang Tu